All

Expensya
13 December 2018

Expensya

Expensya reinvents expense reporting thanks to innovative features and to the latest technology trends. From receipts to accounting, their web and mobile solution automates...

Read more
Expensya raises 4M€ in Series A Financing co-lead by ISAI and Seventure Partners
13 December 2018

Expensya raises 4M€ in Series A Financing co-lead by ISAI and Seventure Partners

The company, that develops and sells an innovative expense reports software, aims at spurring its international development.

Read the press release
Galecto Biotech Raises €79 Million in Series C Financing Co-Led by Ysios Capital and OrbiMed to Advance Galectin Inhibitor to Late-Stage Clinical Development
26 October 2018

Galecto Biotech Raises €79 Million in Series C Financing Co-Led by Ysios Capital and OrbiMed to Advance Galectin Inhibitor to Late-Stage Clinical Development

Proceeds to fund Phase 2/3 trial of inhaled TD139 in idiopathic pulmonary fibrosis (IPF) and advancement of oral and ocular pipeline candidates into clinical studies

Read the press release
Our Responsible Investment Annual Report is available online
10 October 2018

Our Responsible Investment Annual Report is available online

Click to upload our Responsible Investment Report

Read more
Vedanta Biosciences Announces Successful Phase 1a/1b Data Demonstrating Safety, Tolerability, and Proof of Mechanism for Lead, Rationally Defined Bacterial Consortium Product Candidate, VE303
4 October 2018

Vedanta Biosciences Announces Successful Phase 1a/1b Data Demonstrating Safety, Tolerability, and Proof of Mechanism for Lead, Rationally Defined Bacterial Consortium Product Candidate, VE303

Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally defined consortia of human...

Read the press release

By continuing your browsing on this site, you accept the use of cookies to carry out statistics of anonymous visits. Read more

Authorize Refuse